OnCo
ideasIdea

A urine DNA test to decide who with blood in the urine needs a camera test

Most people referred for blood in the urine do not have bladder cancer, yet all get cystoscopy. A urine DNA or methylation test could safely spare most of them.

Urinary methylation and mutation assays report high negative predictive value. Propose an RCT in the haematuria pathway: biomarker-negative patients randomised to deferred versus immediate cystoscopy, with missed muscle-invasive cancer as the safety endpoint and cystoscopies avoided as efficacy.

Hypothesis
Biomarker triage reduces cystoscopies by at least half with a missed high-grade cancer rate below 0.5%.
Rationale
Bladder cancer prevalence in haematuria referrals is 5-10%; cystoscopy capacity is a rate-limiting step for urology worldwide.
What would test it
Run a 3,000-patient RCT with a pre-agreed non-inferiority margin.
Maturity
early clinical
Who has to act
clinic
Cost to try
Medium ($1M to $50M)
Years to first evidence
3
Bottlenecks it attacks
  • Most lethal cancers are found late · Screening exists for only a few cancers. Pancreatic, ovarian, liver, oesophageal and most lung cancers are found when cure is unlikely.
  • Overdiagnosis and false alarms · Finding more cancer is not the same as saving lives. Screening also finds cancers that would never have hurt anyone, and treats them.

Connected

8top

Pages like this

not linked directly; found by shared links